ELTX

Elicio TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$16.00

+39.3% vs current

Most likely

Base case

40%

Probability

Target price

$11.00

-4.3% vs current

B-

Bear case

35%

Probability

Target price

$6.50

-43.4% vs current

AI sentiment snapshot

Latest data as of 2026-04-15

AI commentary

This remains a cautious monitoring view, not a high-conviction bullish call. Primary-source context is solid, but the deterministic prior is neutral, evidence quality is only moderate, catalyst density is low, and the stock is still dominated by one near-term clinical event plus financing risk.

RankAlpha Sentiment Codex - 2026-04-15

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30eventAMPLIFY-7P primary DFS analysis in 1H 2026High impact

Management said the event-driven primary disease-free survival analysis for the Phase 2 AMPLIFY-7P trial remains expected in 1H 2026, with trial completion and readout still the central value driver for ELI-002 7P in resected mKRAS PDAC. [#PR-2026-03-12] [#10-K-2026-03-12]

2026-06-30catalystNeoadjuvant investigator-initiated Phase 1 study startHigh impact

The Memorial Sloan Kettering/Lustgarten Foundation investigator-initiated neoadjuvant Phase 1 study of ELI-002 7P with mFOLFIRINOX and optional anti-PD-1 was disclosed as expected to commence in H1 2026, offering a secondary platform-expansion signal if enrollment begins on time. [#PR-2025-09-29]

2026-07-31catalystATM financing and runway overhang into Q3 2026High impact

The March 16, 2026 8-K established a new up-to-$100.0 million at-the-market facility, while the 10-K states there is substantial doubt about the company’s ability to continue as a going concern and management expects cash on hand to fund operations only into Q3 2026; this supports operations but keeps dilution risk front and center. [#8-K-2026-03-16] [#10-K-2026-03-12] [#PR-2026-03-12]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-15 • Updated nightlySource: Internal modelMethodology